TCTR20210725001Enrolling By Invitation不适用
A low dose monthly emicizumab for prophylaxis among Thai hemophilia A patients with and without inhibitor
Division of Pediatric Hematology0 个研究点目标入组 10 人开始时间: 2021年7月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 24 Months 至 45 Years（—）
- 性别
- Male
入选标准
- •1. Patients with moderate to severe hemophilia A (factor VIII activity less than 3%) with and without inhibitor.
- •2. Age 2 years or older
- •3. Patients are able to access to treatment for acute bleeding within 2 hours
- •4. Experienced low-dose prophylaxis or at least 5 bleeds in 6 months in episodic treatment
排除标准
- •1. Other coagulation disorders
- •2. Liver or renal diseases
- •3. Conditions that may increase risk of bleeding
- •4. Concomitant disease, condition or abnormality that could interfere with study conduct or pose unacceptable risk to patients
- •5. Required elective surgery
研究者
相似试验
已完成
3 期
PHASE III STUDY OF EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A (AGEHA)Acquired hemophilia AJPRN-jRCT2080225056Chugai Pharmaceutical Co., Ltd.14
尚未招募
4 期
A study about how well emicizumab prevents bleeding in haemophilia A patients and its overall impact on their health outcomesCTRI/2024/07/069770Rnt medical College
进行中（未招募）
1 期
Imiquimod therapy after surgical removal of anal HPV-lesions to reduce likelihood of recurrenceEUCTR2017-000842-23-ATMedical University Innsbruck200
已完成
3 期
A randomized controlled trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancerJPRN-UMIN000014780ational Hospital Organization, Thoracic Oncology Network Research Group280
进行中（未招募）
3 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without InhibitorsSevere Hemophilia ANCT04431726Hoffmann-La Roche55